- Home
- RXST
RXST
RxSight Inc.
as 11-15-2024 3:39pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $61.63 | AVG Volume (30 days): | 663.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.07 - $66.54 | Next Earning Date: | 11-07-2024 |
| Revenue: | $128,293,000 | Revenue Growth: | 67.52% |
| Revenue Growth (this year): | 60.19% | Revenue Growth (next year): | 34.96% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | RXST | See remarks | Nov 12 '24 | Sell | $46.13 | 1,330 | $61,356.23 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Nov 7 '24 | Sell | $55.25 | 3,100 | $170,494.64 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Nov 4 '24 | Sell | $51.36 | 3,100 | $158,247.08 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Oct 22 '24 | Sell | $49.68 | 3,100 | $154,001.18 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Oct 16 '24 | Sell | $50.25 | 6,205 | $309,850.38 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Oct 10 '24 | Sell | $49.70 | 9,305 | $462,457.53 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Sep 26 '24 | Sell | $49.12 | 6,205 | $305,000.14 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Sep 20 '24 | Sell | $53.12 | 6,200 | $328,164.02 | 42,246 | |
| Goldshleger Ilya | RXST | See remarks | Sep 17 '24 | Sell | $56.11 | 3,100 | $173,944.10 | 42,246 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 11/15/2024
MT Newswires
2 days ago
RxSight Insider Bought Shares Worth $1,014,570, According to a Recent SEC Filing
Simply Wall St.
8 days ago
RxSight, Inc. (NASDAQ:RXST) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
GuruFocus.com
9 days ago
RxSight Inc (RXST) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Market ...
Zacks
9 days ago
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
GlobeNewswire
10 days ago
RxSight, Inc. Reports Third Quarter 2024 Financial Results
GuruFocus.com
11 days ago
What To Expect From RxSight Inc (RXST) Q3 2024 Earnings
Simply Wall St.
18 days ago
Is It Too Late To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.